期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 63, 期 19, 页码 10594-10617出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.9b02170
关键词
-
资金
- Sichuan Science and Technology Department Project [2017JQ0038]
- Sichuan Provincial People's Hospital Clinical Research and Transformation Fund Key Project [2016LZ03]
Cyclic nucleotide phosphodiesterase 4 (PDE4) specifically hydrolyzes cyclic adenosine monophosphate (cAMP) and plays vital roles in biological processes such as cancer development. To date, PDE4 inhibitors have been widely studied as therapeutics for the treatment of various diseases such as chronic obstructive pulmonary disease, and many of them have progressed to clinical trials or have been approved as drugs. Herein, we review the advances in the development of PDE4 inhibitors in the past decade and will focus on their pharmacophores, PDE4 subfamily selectivity, and therapeutic potential. Hopefully, this analysis will lead to a strategy for development of novel therapeutics targeting PDE4.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据